matinas biopharma (nyse mkt: mtnb) is a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications. the company's proprietary, disruptive technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, making them safer, more tolerable, less toxic and orally bioavailable. the company's lead drug candidate mat2203, currently in phase 2, is an orally-administered, encochleated formulation of amphotericin b (a broad spectrum fungicidal agent). the company has an open investigational new drug (ind) application for mat2501, currently in phase 1, which is an orally-administered, encochleated formulation of amikacin (a broad spectrum aminoglycoside antibiotic agent) for acute bacterial infections, including non-tuberculous mycobacterium (ntm) and multi-drug resistant gram negative bacterial infections. the company's lead anti-infective product candidates, mat2203 and mat2501, position matinas biopharma to bec
Company profile
Ticker
MTNB
Exchange
Website
CEO
Jerome Jabbour
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Matinas BioPharma, Inc. • Matinas BioPharma Nanotechnologies, Inc. ...
MTNB stock data
Latest filings (excl ownership)
8-K
Matinas BioPharma Announces Registered Direct Offering of $10 Million
5 Apr 24
424B5
Prospectus supplement for primary offering
4 Apr 24
8-K
Regulation FD Disclosure
28 Mar 24
8-K
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
27 Mar 24
10-K
2023 FY
Annual report
27 Mar 24
8-K
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
25 Mar 24
8-K
Regulation FD Disclosure
22 Mar 24
8-K
Other Events
22 Mar 24
8-K
Regulation FD Disclosure
26 Feb 24
8-K
Regulation FD Disclosure
20 Feb 24
Transcripts
MTNB
Earnings call transcript
2023 Q3
8 Nov 23
MTNB
Earnings call transcript
2023 Q2
9 Aug 23
MTNB
Earnings call transcript
2023 Q1
10 May 23
MTNB
Earnings call transcript
2022 Q4
16 Mar 23
MTNB
Earnings call transcript
2022 Q3
3 Nov 22
MTNB
Earnings call transcript
2022 Q2
11 Aug 22
MTNB
Earnings call transcript
2022 Q1
12 May 22
MTNB
Earnings call transcript
2021 Q4
8 Mar 22
MTNB
Earnings call transcript
2021 Q3
8 Nov 21
MTNB
Earnings call transcript
2021 Q2
10 Aug 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 6.66 mm | 6.66 mm | 6.66 mm | 6.66 mm | 6.66 mm | 6.66 mm |
Cash burn (monthly) | 1.11 mm | 397.42 k | 2.04 mm | 1.95 mm | 1.47 mm | 1.25 mm |
Cash used (since last report) | 7.97 mm | 2.85 mm | 14.65 mm | 13.95 mm | 10.56 mm | 8.96 mm |
Cash remaining | -1.31 mm | 3.81 mm | -8.00 mm | -7.29 mm | -3.90 mm | -2.30 mm |
Runway (months of cash) | -1.2 | 9.6 | -3.9 | -3.7 | -2.6 | -1.8 |
Institutional ownership, Q3 2023
17.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 49 |
Opened positions | 6 |
Closed positions | 8 |
Increased positions | 8 |
Reduced positions | 8 |
13F shares | Current |
---|---|
Total value | 3.10 bn |
Total shares | 37.21 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 8.75 mm | $1.14 bn |
Vivo Opportunity | 5.99 mm | $7.67 mm |
Vivo Capital IX | 5.27 mm | $7.17 mm |
Sargent Investment | 3.92 mm | $509.99 mm |
BLK Blackrock | 2.50 mm | $325.16 mm |
Geode Capital Management | 1.96 mm | $254.94 mm |
Arkadios Wealth Advisors | 1.40 mm | $181.87 mm |
Neville Rodie & Shaw | 1.16 mm | $150.00 k |
JTC Employer Solutions Trusteee | 775.00 k | $101.00 k |
Jacobs Levy Equity Management | 754.73 k | $98.12 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Dec 23 | Matkovits Theresa | Stock Option Common Stock | Grant | Acquire A | No | No | 0.247 | 1,300,000 | 321.10 k | 1,300,000 |
15 Dec 23 | Thomas Hoover | Stock Option Common Stock | Grant | Acquire A | No | No | 0.247 | 1,000,000 | 247.00 k | 1,000,000 |
15 Dec 23 | Liu Hui | Stock Option Common Stock | Grant | Acquire A | No | No | 0.247 | 1,000,000 | 247.00 k | 1,000,000 |
15 Dec 23 | Kucinski Keith A | Stock Option Common Stock | Grant | Acquire A | No | No | 0.247 | 1,000,000 | 247.00 k | 1,000,000 |
15 Dec 23 | Jabbour Jerome D | Stock Option Common Stock | Grant | Acquire A | No | No | 0.247 | 3,500,000 | 864.50 k | 3,500,000 |
News
In Vivo Efficacy Of Matinas BioPharma's Oral MAT2203 In Pulmonary Mucormycosis Published In Journal Of Antimicrobial Agents And Chemotherapy
30 Apr 24
12 Health Care Stocks Moving In Monday's After-Market Session
1 Apr 24
Matinas BioPharma Hldgs Q4 EPS $(0.03) Down From $(0.02) YoY
27 Mar 24
Matinas BioPharma FY23 EPS $(0.11) Vs $(0.10) YoY
27 Mar 24
Why Is Fungal Infections-Focused Matinas BioPharma Stock Trading Higher On Friday?
22 Mar 24
Press releases
Matinas BioPharma Prices $10 Million Registered Direct Offering
3 Apr 24
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
27 Mar 24
Three Patients with Invasive Fusarium Infection in Matinas BioPharma's Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response
22 Mar 24
Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards
22 Mar 24